Anti-NMDA receptor encephalitis secondary prevention: Difference between revisions

Jump to navigation Jump to search
 
Line 23: Line 23:
[[Category:Disease]]
[[Category:Disease]]
<ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484  }} </ref>
<ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484  }} </ref>
<ref name="pmid21933952">{{cite journal| author=Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ| title=Cognitive deficits following anti-NMDA receptor encephalitis. | journal=J Neurol Neurosurg Psychiatry | year= 2012 | volume= 83 | issue= 2 | pages= 195-8 | pmid=21933952 | doi=10.1136/jnnp-2011-300411 | pmc=3718487 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21933952  }} </ref>
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 17:36, 13 May 2023

Anti-NMDA receptor encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anti-NMDA receptor encephalitis from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anti-NMDA receptor encephalitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anti-NMDA receptor encephalitis secondary prevention

CDC on Anti-NMDA receptor encephalitis secondary prevention

Anti-NMDA receptor encephalitis secondary prevention in the news

Blogs on Anti-NMDA receptor encephalitis secondary prevention

Directions to Hospitals Treating Anti-NMDA receptor encephalitis

Risk calculators and risk factors for Anti-NMDA receptor encephalitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]

Overview

Secondary prevention of anti-NMDA encephalitis involves strategies aimed at early detection, timely intervention, and management to prevent disease progression and complications. Since anti-NMDA encephalitis often presents with neuropsychiatric symptoms, prompt recognition and appropriate referral to specialized medical care are crucial.

Secondary Prevention

Secondary prevention measures include:

  • 1. Education and Awareness: Increasing awareness among healthcare professionals, including neurologists, psychiatrists, and primary care providers, about the clinical presentation and diagnostic criteria of anti-NMDA encephalitis can facilitate early identification and intervention.
  • 2. Diagnostic Workup: Implementing a standardized diagnostic workup, including brain imaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and antibody testing, can aid in confirming the diagnosis and guiding appropriate treatment.
  • 3. Timely Initiation of Treatment: Early initiation of immunotherapy, such as corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab, has been associated with better outcomes and reduced morbidity and mortality. Prompt removal of the underlying tumor, if present, is also important.
  • 4. Multidisciplinary Approach: Collaboration among neurologists, psychiatrists, immunologists, and other specialists is essential for a comprehensive evaluation, management, and follow-up care of patients with anti-NMDA encephalitis.

References

[1] [2] Template:WH Template:WS

  1. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". Lancet Neurol. 13 (2): 167–77. doi:10.1016/S1474-4422(13)70282-5. PMC 4006368. PMID 24360484.
  2. Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ (2012). "Cognitive deficits following anti-NMDA receptor encephalitis". J Neurol Neurosurg Psychiatry. 83 (2): 195–8. doi:10.1136/jnnp-2011-300411. PMC 3718487. PMID 21933952.